MAGI-2 Is a Sensitive and Specific Marker of Prostatic Adenocarcinoma: A Comparison With AMACR.
Am J Clin Pathol
; 146(3): 294-302, 2016 Sep.
Article
in En
| MEDLINE
| ID: mdl-27543977
ABSTRACT
OBJECTIVES:
We compared the utility of membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 (MAGI-2) and α-methylacyl CoA (AMACR) by immunohistochemistry in diagnosing prostatic adenocarcinoma.METHODS:
Seventy-eight radical prostatectomies were used to construct three tissue microarrays with 512 cores, including benign prostatic tissue, benign prostatic hyperplasia, high-grade prostatic intraepithelial neoplasia (HGPIN), and adenocarcinoma. AMACR and MAGI-2 immunohistochemistry were evaluated by visual and image analysis.RESULTS:
MAGI-2 and AMACR were significantly higher in adenocarcinoma and HGPIN compared with benign tissue. At H-score cutoffs of 300 and 200, MAGI-2 was more accurate in distinguishing benign from malignant glands than AMACR. Areas under the curve by image and visual analysis were 0.846 and 0.818 for MAGI-2 and 0.937 and 0.924 for AMACR, respectively. The accuracy of MAGI-2 in distinguishing benign from malignant glands on the same core was higher (95% vs 88%).CONCLUSIONS:
MAGI-2 could represent a useful adjunct for diagnosis of prostatic adenocarcinoma, especially when AMACR is not discriminatory.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prostate
/
Prostatic Hyperplasia
/
Prostatic Neoplasms
/
Adenocarcinoma
/
Carrier Proteins
/
Biomarkers, Tumor
/
Prostatic Intraepithelial Neoplasia
/
Racemases and Epimerases
Type of study:
Diagnostic_studies
Limits:
Humans
/
Male
Language:
En
Journal:
Am J Clin Pathol
Year:
2016
Document type:
Article